Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Chemotherapy Induced Neutropenia 2Prostatic Neoplasms 1Lymphoma 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × pegylated granulocyte colony-stimulating factor, human × Clear all
NCT02963389 2019-01-15

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

Dong-A ST Co., Ltd.

Phase 1 Completed
27 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡